Preimplantation Genetic Haplotyping
Preimplantation Genetic Haplotyping (PGH) is a clinical method of preimplantation genetic diagnosis (PGD). PGH was first developed in 2006 at London's Guy's Hospital and greatly advances PGD by using DNA fingerprinting rather than identifying the actual genetic signature (such as point mutations).
Compared with previous PGD techniques, PGH allows:
- The ability to screen male embryos
- A much greater number of individual tests
- Increased reliability
- Higher success rate
PGH has been used to screen for:
- cystic fibrosis
- Duchenne muscular dystrophy
- Huntington's disease
- Spinal Muscular Atrophy
- Alport's syndrome
- Von Hippel-Lindau disease
- Sickle-cell disease
- and recurrent Hydatidiform mole
- ↑ 1.0 1.1 Renwick PJ, Trussler J, Ostad-Saffari E, et. al (2006-07-13). "Proof of principle and first cases using preimplantation genetic haplotyping--a paradigm shift for embryo diagnosis" (subscription required). Reprod Biomed Online 13 (1): 110-9. PMID 16820122.
Revolutionary new technology will allow more couples to benefit from preimplantation genetic diagnosis. PGH Press Release. 2006 Guy's and St Thomas' NHS Foundation Trust (2006-09-12). Retrieved on 2006-09-26.
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies